Epidermal growth factor ameliorates autosomal recessive polycystic kidney disease in mice

V H Gattone1, D A Lowden, B D Cowley

  • 1Department of Anatomy and Cell Biology, University of Kansas Medical Center, Kansas City 66160, USA.

Insights

Epidermal growth factor (EGF) administration improved kidney function and survival in a mouse model of autosomal recessive polycystic kidney disease (ARPKD). This suggests EGF is crucial for collecting duct maturation and preventing cyst development in ARPKD.

Area of Science:

  • Nephrology
  • Developmental Biology
  • Genetics

Background:

  • Cystic kidney disease in C57BL/6J mice (cpk gene) mimics human autosomal recessive polycystic kidney disease (ARPKD).
  • Affected mice display immature collecting duct epithelium and reduced renal epidermal growth factor (EGF).

Purpose of the Study:

  • To investigate if reduced renal EGF contributes to collecting duct cyst development in ARPKD.
  • To determine if exogenous EGF administration can mitigate ARPKD progression.

Main Methods:

  • Daily subcutaneous EGF administration to C57BL/6J-cpk mice from postnatal days 3-9.
  • Sham or albumin treatments served as controls.
  • Assessed PKD development, renal failure, survival rates, and sulfated glycoprotein-2 expression.

Main Results:

  • EGF treatment significantly retarded PKD development and reduced renal failure.
  • EGF administration prolonged survival in cystic mice.
  • Reduced sulfated glycoprotein-2 expression indicated enhanced collecting duct cell maturation.

Conclusions:

  • Decreased EGF is implicated in promoting collecting duct cyst enlargement in ARPKD.
  • EGF treatment promotes collecting duct cell maturation, suggesting a therapeutic potential for ARPKD.

Related Concept Videos